OpenAI has introduced GPT-Rosalind, a new artificial intelligence model designed to support scientific research across fields such as biochemistry, drug discovery, and translational medicine.
Named after pioneering scientist Rosalind Franklin, the model is aimed at accelerating early-stage research by assisting with complex, multi-step scientific tasks.
According to the company, GPT-Rosalind can help researchers synthesise evidence, generate hypotheses, plan experiments, and analyse scientific data. It also allows users to query databases, review recent academic papers, and suggest new experimental approaches.
The model is built on OpenAI’s latest internal systems and is being made available as a research preview through ChatGPT, Codex, and its API for qualified users under a controlled access framework.
OpenAI is also launching a Life Sciences plugin for Codex, which connects researchers to more than 50 scientific tools and data sources.
The company said it is already working with major organisations, including Amgen, Moderna, and Thermo Fisher Scientific, to integrate the model into research workflows.
The launch comes amid rising demand for AI-powered tools in the pharmaceutical and biotech industries, where companies are seeking to accelerate discovery timelines and reduce research costs.
